The FDA cleared Eversense 365 as the first 1-year integrated continuous glucose monitoring (CGM) system for adults with type ...

Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...

Continuous glucose monitoring, compared with fingerstick tests, was feasible and accurate in an inpatient setting among patients and nurses.

Eversense 365 is said to be the world's first one-year CGM system, offering a new long-term solution for diabetes management.

Dexcom unveiled its Dexcom G7 continuous glucose monitoring (CGM) for people with diabetes age two years and older in ...

New continuous glucose monitoring sensors (small sensors that penetrate the skin to measure glucose levels in real time) are ...

Leveraging rapid technological advances for human health is a global trend, driving the rise of biomedical engineering ...

As part of its ongoing exploration of vocal biomarkers and the role they can play in enhancing health outcomes, Klick Labs ...

Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of ...

TYPE 2 diabetes, more commonly seen in adults, is rising among chil­dren in Trinidad and Tobago.Increasingly unheal­thy ...